Details for Patent: 7,601,758

United States Patent 7,601,758 (Colchicine + Clarithromycin/Erythromycin): Scope, Claim Construction, and Landscape

What does US 7,601,758 claim in plain terms?

US 7,601,758 is directed to a dose-reduction method for colchicine-treated gout flares in humans when the patient is also receiving a macrolide antibiotic that increases colchicine exposure (specifically clarithromycin or erythromycin). The core technique is a defined reduction in colchicine dose to about two-thirds (and in dependent claim ranges, about 50% to 75%) plus a clear “no repeat dosing” timing rule of at least three days, tied to the timing of macrolide administration.

The claims are not about novel colchicine molecules or macrolide compounds. They are about how to dose colchicine under a specific drug-drug interaction risk window.

What is the independent claim 1 actually limited to?

Claim 1 is a method claim with a structured set of limitations that jointly narrow infringement risk to a specific clinical workflow.

Claim 1 key limitations (must all be met)

1. Indication/patient context
   • Treat a gout flare in a human patient.
2. Concomitant co-administration
   • Patient is receiving clarithromycin or erythromycin.
3. Timing of the concomitant antibiotic relative to colchicine
   • Concomitant administration occurs within 1 to 2 days of orally administering the second colchicine dosage amount.
4. Two-step dosage determination
   • Determine a first colchicine dosage amount adapted for oral administration to treat the gout flare in the absence of clarithromycin or erythromycin.
   • Determine a second colchicine dosage amount that is about a two-thirds reduction of the first.
5. Actual administration
   • Administer the second colchicine dosage amount to treat the gout flare.
6. Re-dosing constraint
   • Do not repeat colchicine administration for at least three days.

Practical meaning of the “about two-thirds reduction”

In claim 1, “about a two thirds reduction of the first colchicine dosage amount” reads as the second dose is roughly one-third of the first dose (subject to “about” tolerance). Claim 8 then anchors this with specific mg/day values.

What scope do dependent claims add (claims 2 to 11)?

Claim 2-4: How the “two-thirds reduction” can be achieved

• Claim 2: reduction can be via fewer colchicine doses.
• Claim 3: reduction can be via smaller size of at least one dose.
• Claim 4: reduction can be via both fewer doses and smaller doses.

These clauses expand the ways a practitioner can satisfy the two-thirds reduction requirement, as long as the net effect matches the claimed reduction concept.

Claims 5-7: Patient age and specific macrolide

• Claim 5: patient is an adult.
• Claim 6: adult patient is less than 70 years old.
• Claim 7: the concomitant antibiotic is clarithromycin (erythromycin is not named in this dependent claim).

Claim 8: Numerical dose anchor

• First dose: about 1.8 mg/day
• Second dose: about 0.6 mg/day This is the most concrete “infringement anchor” because it maps the “about two-thirds reduction” to a specific dosing regimen concept.

Claim 9: Specific single-dose + hold rule

• After a single 0.6 mg dose, do not repeat colchicine ingestion for at least three days.

This claim aligns with common gout flare dosing patterns that start with a small oral dose then wait, but only where the macrolide timing rule also applies.

Claims 10-11: Alternative expression of the dose reduction and consolidated constraints

Claim 10 is another independent-like method claim that includes:

• Reduce colchicine dose to about 50% to about 75% of a manufacturer recommended dose in the absence of clarithromycin/erythromycin.
• Do not repeat colchicine administration for at least three days.
• Concomitant macrolide administration is within 1 to 2 days of orally administering the “second” reduced dose (as referenced).
• Purpose statement: reduce occurrence of colchicine toxicity.

Claim 11 nails the reduced dose:

• Reduced colchicine dosage amount is about 0.6 mg/day.

How does the claim set define infringement risk? (element-by-element)

US 7,601,758 is an interaction-specific dosing claim. An infringing use must satisfy all required elements in the selected claim.

Element mapping for claim 1

Where infringement is most likely to be captured

• When prescribers implement a colchicine reduction to around 0.6 mg/day or an equivalent “about two-thirds reduction” scheme, while withholding further dosing for at least three days in the presence of clarithromycin/erythromycin.
• When the antibiotic is active near the first colchicine dosing event (1 to 2 days), not months away.

Where infringement can fall away

• If colchicine is not reduced to the claimed relationship.
• If colchicine is re-dosed within the three-day window.
• If the antibiotic is not clarithromycin/erythromycin.
• If macrolide administration timing does not fall within the 1 to 2 day window tied to the colchicine second dose.

What dosage ranges are covered, and how do claims overlap?

There are two main quantitative frameworks:

Framework A: “two-thirds reduction” (claim 1 and dependent anchors)

• Claim 8: First ≈ 1.8 mg/day, Second ≈ 0.6 mg/day
• This supports an interpretation where the second dose is about one-third of the first.

Framework B: “50% to 75% of manufacturer dose” (claim 10)

• Reduced dose is about 50% to about 75% of manufacturer recommended colchicine dosage amount absent macrolide.
• Claim 11 then specifies a numerical reduced dose: about 0.6 mg/day.

Relationship between Framework A and B

The two frameworks do not perfectly align without knowing the “manufacturer recommended colchicine dosage” baseline referenced by claim 10. But claim 8 and 11 provide strong numeric coverage that a design-around cannot avoid if it still uses the same practical dosing pattern.

What is the effective “timing system” the patent enforces?

The claims use two timing constructs:

1. Macrolide-concomitance timing: antibiotic administration occurs within 1 to 2 days of the second colchicine oral dosing.
2. Colchicine re-dosing timing: no repeat for at least 3 days.

So the method is not just “reduce dose.” It is a reduce + delay regimen tied to macrolide timing.

This combination matters because it limits claims to a specific dosing schedule, not merely a reduced dosage amount.

What patient subsets are explicitly covered?

• Adult patients are explicitly included (claim 5).
• Claim 6 tightens further to adults under 70 years old.
• Independent coverage remains with adults if claim 5 is satisfied; the “under 70” limitation is only for claim 6.

In practice, the presence of an adult limitation in dependent form means the patent can cover a broader population under claim 1, but narrower subgroups under claim 6.

How would a competitor design around the method claims? (scope logic)

Any design-around must avoid at least one claim element. The claim logic suggests the following high-leverage carve points:

• Break the timing window: ensure macrolide administration is not within 1-2 days of the initial reduced colchicine oral dosing event.
• Break the “no repeat” rule: re-dose colchicine within 3 days (note: this may conflict with safety standards, but legally it is a structural difference).
• Break the reduction magnitude: avoid a “two-thirds reduction” (or avoid the corresponding reduced-dose magnitude that maps to ~0.6 mg/day as anchored in claims 8 and 11).
• Use a different concomitant antibiotic: claims are limited to clarithromycin and erythromycin.

Because claims 8 and 11 pin specific dosing values, avoiding 0.6 mg/day may be necessary to reduce risk, but only if it also avoids the broader relationships expressed in claims 1 and 10.

What is the patent landscape around this concept?

US 7,601,758 sits at the intersection of:

• Colchicine toxicity from drug-drug interactions (especially via CYP3A4 and P-gp effects of macrolides), and
• Gout flare dosing protocols that require dose adjustments under interacting therapy.

Landscape implications for freedom to operate (FTO)

This type of method claim typically creates risk for:

• Prescribing protocols that adopt reduced colchicine schedules when clarithromycin or erythromycin is co-administered.
• Clinical pathways, especially those that specify a reduced colchicine dose plus withholding repeat dosing for at least 3 days.

Typical competitor behavior

• Alternative reduced dosing schedules that fall outside the claimed numeric relationships (or avoid the macrolide timing link).
• Switching antibiotics away from clarithromycin/erythromycin where feasible.
• Using different colchicine administration patterns that differ in re-dosing interval.

Likely non-coverage

The patent is not about:

• IV colchicine,
• prophylaxis for chronic gout (not stated in the excerpts),
• other antibiotics besides clarithromycin/erythromycin,
• colchicine formulations (unless method implicitly covers only oral dosing as in claim 1).

What should R&D and clinical teams treat as the claim “center of gravity”?

The “center of gravity” is a dosing and timing instruction set:

• Concomitant clarithromycin/erythromycin
• Within 1-2 days of the initial (reduced) colchicine oral dose
• Colchicine dose is reduced to roughly one-third of the non-macrolide dose (claim 1) or to 50% to 75% of manufacturer recommended dosing (claim 10)
• No repeat dosing for at least 3 days
• Numeric anchor around 0.6 mg/day (claims 8 and 11) and single 0.6 mg then hold (claim 9)

Any clinical pathway that matches these structural elements is at elevated infringement risk.

Key Takeaways

• US 7,601,758 claims a method for treating gout flares with colchicine that requires clarithromycin or erythromycin co-administration plus a specific dose reduction and a hard re-dosing hold of at least three days.
• Claim 1 hinges on four joint elements: (i) macrolide timing within 1-2 days, (ii) colchicine dose reduced by about two-thirds, (iii) oral administration, and (iv) no repeat for at least 3 days.
• Dependent claims add enforcement points: adult status, <70 years subset, and numerical dosing anchors around 0.6 mg/day (claims 8 and 11) including single-dose 0.6 mg then no repeat for 3 days (claim 9).
• For FTO and protocol design, the most actionable levers are to break the timing window, break the reduction magnitude, or change the repeat dosing interval, since claim language couples these elements rather than treating them independently.

FAQs

1) Does US 7,601,758 cover concomitant use with azithromycin?
No. The claims are limited to clarithromycin or erythromycin.

2) Is the “no repeat colchicine for at least three days” requirement absolute?
For each claim where it appears, yes. Claim 1 requires not repeating colchicine for at least three days after the second colchicine dosing amount.

3) Is 0.6 mg/day an absolute requirement to fall within the patent?
No, but it is a strong anchor. Claims 8 and 11 expressly recite dosing around 0.6 mg/day and claim 9 covers a single 0.6 mg dose followed by a 3-day hold.

4) Can the two-thirds reduction be achieved by fewer doses instead of smaller doses?
Yes. Claim 2 covers reduction by reducing the number of doses; claim 3 covers reduction by reducing dose size; claim 4 covers both.

5) Does the patent require that the macrolide and colchicine be given on the same day?
No. Concomitant administration is defined as within 1 to 2 days of the colchicine oral dosing.

References

[1] United States Patent 7,601,758 (claims as provided by user text).